SCHEMBL207261

SCHEMBL207261

c1ccc(CCc2ccc(Nc3nc(-c4cccnc4)cs3)cc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.70
NPC1 O15118 10/20 0.70
MAPT P10636 6/20 0.70
SMN1; SMN2 Q16637 5/20 0.70
ALDH1A1 P00352 3/20 0.70
MEN1 O00255 12/20 0.70
KMT2A Q03164 12/20 0.70
GAA P10253 3/20 0.70
PKM P14618 2/20 0.70
LMNA P02545 1/20 0.70
VCP P55072 1/20 0.70
MAPK1 P28482 2/20 0.68
TP53 P04637 2/20 0.65
TDP1 Q9NUW8 2/20 0.65
CASP3 P42574 2/20 0.65
SENP8 Q96LD8 2/20 0.65
SENP7 Q9BQF6 2/20 0.65
SENP6 Q9GZR1 2/20 0.65
NCOA3 Q9Y6Q9 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17539298 0.90 RAB9A (0.66) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL206745 0.89 MEN1 (0.70) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL12639823 0.88 MAPK1 (0.86) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL15587693 0.88 RAB9A (0.62) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL206589 0.87 MEN1 (0.67) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL205576 0.87 MEN1 (0.70) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL205189 0.86 MEN1 (0.66) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL205575 0.86 MEN1 (0.69) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL17539701 0.86 RAB9A (0.67) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL15587795 0.86 RAB9A (0.63) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US claimed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US claimed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 RAB9A 1357/4885NPC1 62/4885MAPT 2207/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 RAB9A 1357/4885NPC1 62/4885MAPT 2207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.